Dendreon Expansion Approved by FDA

With the additional workstations, Dendreon expects to have approximately 225 infusion centers prepared to treat their first patient by the end of the 2Q11.

Dendreon Corp. received approval from the FDA for the expansion of its manufacturing facility in NJ. This will allow the company to significantly increase the availability of Provenge (sipuleucel-T), a treatment for metastatic castrate resistant (hormone refractory) prostate cancer.

The FDA approved Provenge last April. At that time Dendreon had 12 workstations at its NJ facility to supply the drug. The FDA has approved 36 additional workstations, bringing the total workstation count to 48. With the additional workstations, Dendreon expects to have approximately 225 infusion centers prepared to treat their first patient by the end of the 2Q11, approximately 450 infusion centers by 4Q11, and approximately 500 by the end of the year.

"The significant 4.1 month median survival benefit PROVENGE de